Table 3.

Use of TKI in 7 Patients with Ph⁺ ALL.

PatientNo.	TKI Before HSCT	TKI in Conditioning	TKI after HSCT			Relapse
			Starting Time of TKI (days)	Usage of TKI	Time of TKI Withdrawal (days)
16	Dasatinib (100 mg/d) + chemotherapy	Dasatinib (100 mg/d)	60	Imatinib (400 mg/d)*	276	Yes
17	Imatinib (400 mg/d) + chemotherapy	Imatinib (400 mg/d)	61	Imatinib (400 mg/d)	170	Yes
18	Dasatinib (100 mg/d) + chemotherapy	Dasatinib (100 mg/d)	59	Dasatinib (100 mg/d)	223	Yes
19	Imatinib (400 mg/d) + chemotherapy	Imatinib (400 mg/d)	65	Imatinib (400 mg/d)	365	No
20	Imatinib (400 mg/d) + chemotherapy	Imatinib (400 mg/d)	54	Imatinib (400 mg/d)	379	No
21	Dasatinib (100 mg/d) + chemotherapy	Dasatinib (100 mg/d)	66	Dasatinib (100 mg/d)	156	No
			157	Imatinib (400 mg/d)#	365
22	Imatinib (300 mg/d)§ + chemotherapy	Imatinib (300 mg/d)	57	Dasatinib (100 mg/d)	366	No

TKI, tyrosine kinase inhibitor; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation.

*As the patient suffered from diabetes mellitus complicated with fundus disease, dasatinib was replaced with imatinib after transplantation. ^#Dasatinib was replaced with imatinib at 157 days after transplantation because of repeated pleural effusion after taking dasatinib.

^§The patient was intolerant to imatinib (400 mg/d), accompanied by severe nausea and vomiting, so imatinib was reduced to 300 mg/d.